The current study aims to evaluate the risk of developing urinary tract infections if patients with type 2 diabetes take SGLT2 inhibitors and determine those factors which make these patients more prone to develop this undesired complication. This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.